ExonHit Launches Mouse Genome SpliceArray™ for use in Human Disease Modeling Studies

ExonHit Therapeutics S.A. has announced the availability of its new SpliceArray™ for use in studying mouse models of human disease.

Using the high resolution expression profiling analysis, the company identifies transcripts coding for new protein variants that may be involved in various genetic disorders such as oncology, central nervous system, or immune system disorders. This mouse SpliceArray™ products represent the achievement of more two years of work by the R&D team after the launch of the Human genome SpliceArray™ in 2007 and the rat genome SpliceArray™ earlier this year.

"ExonHit has added another important species to its target discovery services portfolio. This addition will expand our ability to service scientists who use the mouse as a disease model, as well as our own discovery programs for novel therapeutic targets and biomarkers," said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics.

"These new Mouse SpliceArray™ products will further accelerate the understanding of mechanism of action and ultimately boost the discovery and validation of new therapeutics for ExonHit, using the Mouse as a disease model system, especially in the fields of oncology and CNS disease; this unique approach enabling to save months of preclinical development time," stated Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics.